CURRICULUM VITAE

KARL E. ANDERSON, M.D.                                                                                       February 2, 2006

PRESENT POSITION AND ADDRESS: 

April 1987-Present:                 Professor, Departments of Preventive Medicine and Community Health (Division of Human Nutrition), Internal Medicine (Division of Gastroenterology), and Pharmacology and Toxicology

September 1990-Present:                Director, Division of Human Nutrition

December 1993-Present:                Associate Program Director, General Clinical Research Center

September 1998-Present:                Director, Clinical Research Education Office. 

Office:                            Ewing Hall (3.102L), 700 Harborside Drive, The University of Texas Medical Branch, Galveston, Texas 77555-1109.

Telephone: 409-772-4661.  FAX: 409-772-6287.  Email: kanderso@utmb.edu. 

BIOGRAPHICAL:

Born:                              May 16, 1940.  Buffalo, New York

Citizenship:                   U.S.A.

Married:                         Mary Patricia Wood (Patty), Galveston, TX,  2000

Children:                        Matthew Dana, b. 1984; Gillian Carol, b. 1986; Jeffrey Karl, b. 1990

Residence:                     4726 Caduceus Place, Galveston, TX 77551. Telephone, 409-744-5737

EDUCATION AND POSTGRADUATE TRAINING:

August 1958-June 1960                 The College of Wooster, Wooster, Ohio

August 1960- June 1962                 The Johns Hopkins University, Baltimore, Maryland (B.A. Degree, 6/1962)

August 1960- June 1965                The Johns Hopkins University School of Medicine (M.D. Degree, 6/8/1965)

July 1965- June 1967                  Internship and Residency, Internal Medicine, Vanderbilt University Hospital, Nashville, Tennessee.

July 1967- June 1968                 Residency, Internal Medicine, The New York Hospital-Cornell Medical Center, New York, N. Y.

July 1968- June 1970                Fellowship in Gastroenterology, The New York Hospital-Cornell Medical Center, New York, N. Y.

PROFESSIONAL AND TEACHING EXPERIENCE:

 

1970-1971                       Instructor in Medicine, Cornell University Medical College, New York, N.Y.

1968-1971                       Guest Investigator, The Rockefeller University, New York, N. Y.

1971-1973                       Clinical Investigation Department, U.S. Naval Medical Research Unit No.2, Taipei, Taiwan

1973-1979                       Assistant Professor, The Rockefeller University.  Assistant Professor of Medicine, Cornell University Medical College

1979-1985                       Associate Professor and Physician, The Rockefeller University

1979-1987                       Adjunct Associate Professor of Medicine and Pharmacology, Cornell University Medical College

1982-1987                       Adjunct Attending Physician, Department of Medicine (Gastroenterology), Memorial-Sloan Kettering Cancer Center, New York, N.Y.

1985-1987                       Professor, Departments of Medicine and Pharmacology, and Director, Clinical Research Center, New York Medical College, Valhalla, N.Y. 

1985-1986                       Medical Director, The Institute of Clinical Pharmacology, Valhalla, N.Y.

1985-1990                       Adjunct Professor and Visiting Physician, The Rockefeller University, New York, N.Y. 

April 1987-current                Professor, Departments of Preventive Medicine and Community Health, Internal Medicine, and Pharmacology and Toxicology; Member, Graduate Faculty; Active Member of the Medical Staff, The University of Texas Medical Branch, Galveston, Texas.

April 1987-1990                Associate Director, Division of Human Nutrition, The University of Texas Medical Branch, Galveston, Texas.

September 1990-current                Director, Division of Human Nutrition.  The University of Texas Medical Branch, Galveston, Texas.

December 1993-current                Associate Program Director, General Clinical Research Center, The University of Texas Medical Branch, Galveston, Texas; Acting Program Director, 2002. 

September 1998-current                Director, Clinical Research Education Office, The University of Texas Medical Branch, Galveston, Texas. 

July 2000-2003                Co-Director, Gastrointestinal/Nutrition Course, School of Medicine, The University of Texas Medical Branch, Galveston, Texas. 

RESEARCH ACTIVITIES:

A.  Area of Research:                  Nutritional pharmacology, including effects of diet on drug metabolism

Porphyrias and other disorders of heme metabolism in man. 

B.  Grant Support:  (since 1986)

 

 

 

 

Funding Period

Agency

Title

 Direct Costs

Total Costs

Start

End

USPHS-FDA Orphan Drug Program

LHRH Analogue for Prevention of Porphyric Attacks

$115,338

$170,934

9/30/86

1/31/90

American Porphyria Foundation

Porphyria Research Fund

$2,000

$2,000

8/1/87

7/31/96

TAP Pharmaceuticals

Porphyria Research Fund

$4,706

$4,706

8/1/87

7/31/96

American Porphyria Foundation

Porphyria Research Fund

$1,000

$1,000

8/1/87

7/31/96

Rockefeller University

Comparison of the Effects of Diet and Cimetidine on Hepatic Drug Oxidation Rates in Man

$35,000

$35,000

10/1/87

8/31/93

USPHS-FDA Orphan Drug Program

Erythropoietin for  Hemodialysis-Associated Porphyria

$53,556

$75,097

1/1/89

12/31/91

R. W. Johnson Pharmaceutical Research Institute

Histrelin for Prevention of Porphyria Attacks

$24,500

$26,950

6/1/89

6/30/92

American Porphyria Foundation

Nutritional Factors in Acute Intermittent Porphyria

$1,000

$1,000

5/4/89

7/31/96

American Porphyria Foundation

Nutritional Factors in Acute Intermittent Porphyria

$5,000

$5,000

8/5/89

7/31/96

American Porphyria Foundation

Treatment of Acute Porphyrias with Heme Arginate

$5,000

$5,000

11/1/90

7/31/96

Amgen, Inc.

Studies on the treatment of porphyria cutanea tarda associated with hemodialysis

$36,364

$40,000

2/1/91

8/31/97

Metabolic Solutions, Inc. (NIH SBIR Grant collaborative agreement)

Effects of Diet on Caffeine and Methacetin Breath Tests

$6,500

$9,425

4/1/92

4/1/93

 

Intramural Small Grant, University of Texas Medical Branch (Guion Pool Keating Cancer Fund and the UTMB Annual Fund)

Chloroquine to Control Photosensitivity from Therapeutic Porphyrins

$12,500

$12,500

4/1/92

3/31/93

 

Grant Support (cont'd):

 

 

Direct

Total

Funding Period

Agency

Title

 Costs

Costs

Start

End

American Porphyria Foundation

Endocrine Manipulation for Cyclic Attacks of Porphyria

$5,000

$5,000

8/1/92

4/30/94

USPHS-FDA Orphan Drug Program

Heme Arginate for Treatment of Acute Porphyria

$231,240

$339,923

8/1/92

7/31/95

Haskell B. Smith

Bequest for Porphyria Research

$23,284

$23,284

9/1/92

3/31/94

Amgen, Inc.

Studies on the treatment of porphyria cutanea tarda associated with hemodialysis

$44,000

$48,400

2/1/93

7/31/97

Leiras Oy Pharmaceuticals

Heme Arginate for Acute Porphyria

$225,344

$247,878

3/1/93

Open

American Porphyria Foundation

Drug Safety in Porphyria

$10,000

$10,000

5/1/94

7/31/96

Pfizer, Inc.

An Open Study to Compare the Safety, Toleration and Pharmacokinetics of Oral CP-99,219 in Patients with Chronic Hepatic Insufficiency and in Healthy Subjects

$208,815

$260,525

5/1/94

7/31/97

USPHS-FDA Orphan Drug Program

Heme Arginate for Treatment of Acute Porphyria

$362,419

$541,816

8/1/95

7/31/98

Pfizer, Inc.

Phase I, Multiple Dose Open Study Designed to Compare the Safety and Pharmacokinetics of Ziprasidone in Subjects with Normal Hepatic Function to Subjects with Hepatic Impairment

$50,544

$67,392

11/7/96

7/31/97

American Porphyria Foundation

Telemedicine in Porphyria

$15,000

$15,000

1/1/97

Open

DUSA Pharmaceuticals

A long term study of acute intermittent porphyria

$36,750

$45,973

7/7/97

9/30/98

USPHS-FDA Orphan Drug Program     FD-R-001459

Tin Mesoporphyrin and Heme Therapy in Acute Porphyria

$591,884

$887,826

9/30/97

4/30/03

USPHS-National Heart Lung and Blood Institute

K30 HL04126

Clinical Research Education Program at UTMB

$924,377

$997,699

6/1/99

5/31/05

American Porphyria Foundation

Drug Safety in Acute Porphyria

$10,000

$10,000

8/1/00

Open

USPHS-NIH

K07 HL04326-01

Development of a Longitudinal Nutrition Curriculum

(Subcontract; PI: Marilyn Edwards, PhD, UT Houston)

$30,825

$33,291

4/1/00

3/31/02

USPHS-National Institute on Alcohol Abuse and Alcohol

1-RO1 AA12852

Alcohol-induced cytochromes P450 in HCV/HIV oxidative injury (Subcontract; PI: Steven Shedlofsky, MD, U KY)

$62,250

$92,752

9/30/00

9/29/04

US Army

BC004028

 

Soybean Diet and Breast Density (PI: Lee-Jane Lu, PhD)

$2,001,452

$2,983,163

9/1/01

8/31/07

American Institute for Cancer Research

Comparative Hormonal Effects of Diets Containing Soy and Animal Protein

$149,920

$164,912

9/1/01

12/30/05

American Porphyria Foundation

Drug Safety in Acute Porphyria (support for further studies)

$15,000

$15,000

10/1/02

Open

NIH 1RO1CA95545-01A1

Mammographic Density and Soy Isoflavones

(PI: Lee-Jane Lu, PhD)

$631,881

$1,418,535

09/15/03

08/31/07

 

 

 

 

 

Funding Period

Agency

Title

 Direct Costs

Total Costs

Start

End

Zymenex (formerly HemeBiotech) A/S, Copenhagen, Denmark

A multicentre, double-blind, randomized, placebo-controlled, parallel group trial investigating the efficacy and safety to Porphozym™ (recombinant human porphobilinogen deaminase) in the treatment of acute attacks in AIP

$113,500

$14,188

4/23/03-

4/26/06

USPHS-NIH

(funding to UTMB through Wyle Laboratories)

1RO1GM64797

(Co-investigator; PI:  Putscha, L.) -

Bioavailability and Pharmacodynamics of Promethazine in Human Subjects

~$100,000

~$100,000

8/10/02

11/30/05

USPHS-FDA Orphan Drug Program     FD-R-002604

Hydroxychloroquine vs. Phlebotomy for Porphyria Cutanea Tarda

$584,204

$861,049

9/30/05

9/30/08

USPHS-National Heart Lung and Blood Institute

K30 RR022276

Clinical Research Education Program at UTMB

$1,388,890

$1,500,000

6/1/05

5/31/10

 

 

 

 

 

 

 

COMMITTEE RESPONSIBILITIES:

A.  National:

Gastroenterology and Clinical Nutrition Review Group, National Institutes of Health, Bethesda, Maryland, 1980-1982.

Scientific Advisory Board, The American Porphyria Foundation, Houston, Texas, 1982-current.  Chairman, 1982-1987, 2001-present.

American Society for Clinical Pharmacology and Therapeutics: Membership Committee 1985-1991, Co-chairman 1986-1987, Chairman 1987-1990; Chairman, Section on Gastrointestinal, Endocrine and Metabolic Diseases 1990-1993. 

Gastroenterology Advisory Panel, The United States Pharmacopeial Convention, Inc., 1991-current; Chairman and Member of Council of Experts, 2000-current. 

Board of Scientific and Policy Advisors, American Council on Science and Health, 2000-current. 

 

B.  UTMB:

Nutrition Care Committee, The University of Texas Medical Branch, Galveston, Texas, 1987-1990.

Committee on Research, The University of Texas Medical Branch, Galveston, Texas, 1989-1992, Chairman 1991-1992. 

General Clinical Research Center Scientific Review Committee, 1993-2003; Chairman 2001-2003. 

General Clinical Research Center Advisory Committee, ex-officio, 1993-current. 

John Sealy Memorial Endowment Fund for Biomedical Research Grant Review Committee, ad hoc member, 1995. 

Institutional Review Board, The University of Texas Medical Branch, Galveston, Texas, 1996-1999. 

Clinical Research Education Office Steering Committee, Chairman, 1999-current. 

Clinical Research Education Office Advisory Committee, ex-officio, 1999-2005. 

Mission Based Management Task Force/Research Task Force, The University of Texas Medical Branch, Galveston, Texas, 1999-2000. 

Nominating Committee, The University of Texas Medical Branch, Galveston, Texas, 2000-2002. 

M.D.-Ph.D. Combined Degree Program Advisory Committee, and the Curriculum Subcommittee, Graduate School for Biomedical Sciences, The University of Texas Medical Branch, Galveston, Texas, 2000-current. 

Education and Research Committee, Joint Clinical Enterprise Group, School of Medicine and the University of Texas Medical Branch Hospital, 2006-current. 

C.  Departmental:

Residency Planning Committee, Department of Preventive Medicine and Community Health, The University of Texas Medical Branch, Galveston, Texas, Chairman 1987-1989.

Executive Committee, Department of Preventive Medicine and Community Health, The University of Texas Medical Branch, Galveston, Texas, 1987-current.

Long Range Planning Committee, Department of Preventive Medicine and Community Health, the University of Texas Medical Branch, Galveston, Texas, 1987-1990.

Medical Course Curriculum Committee, Department of Preventive Medicine and Community Health, The University of Texas Medical Branch, Galveston, Texas, 1987-1988.

Steering Committee for Departmental Review, Department of Preventive Medicine and Community Health, the University of Texas Medical Branch, Galveston, Texas, 1989-1990. 

Research Committee (Chairman), Department of Preventive Medicine and Community Health, the University of Texas Medical Branch, Galveston, Texas, 1989-1990. 

Curriculum Committee and Faculty Affairs Subcommittee, Graduate Program in Preventive Medicine and Community Health, 1995-1997. 

Seminar Committee (Chairman), Department of Preventive Medicine and Community Health, the University of Texas Medical Branch, Galveston, Texas, 1994-1997. 

Appointment, Promotion and Tenure Committee, and Post-Tenure Review Committee, Department of Preventive Medicine and Community Health, the University of Texas Medical Branch, Galveston, Texas, 1997-2001, 2005-2006; Chairman, 1999-2001. 

Graduate Policy Committee, Program in Preventive Medicine and Community Health, Graduate School of Biomedical Science, the University of Texas Medical Branch, Galveston, Texas, 1999-current. 

Gastrointestinal-Nutrition Course Committee, Integrated Medical Curriculum (2nd Year), School of Medicine, the University of Texas Medical Branch, Galveston, Texas, 2003-current. 

Office of Nursing Research and Scholarship Advisory Committee, School of Nursing, the University of Texas Medical Branch, Galveston, Texas, 2003.

Comprehensive Examination Committee, Program in Preventive Medicine and Community Health, Graduate School for Biomedical Sciences, The University of Texas Medical Branch, Galveston, Texas, 2001-2002. 

Strategic Planning Committee, Department of Preventive Medicine and Community Health, 2005-current. 

 

D.  Other:

Isotope Human Use Subcommittee, The Rockefeller University, New York, N.Y., 1978-1985 (Secretary 1982-1985)

Committee on Medical Education, The Rockefeller University, New York, N.Y., 1979-1985

Graduate Medical Advisory Committee, New York Medical College, Valhalla, N.Y., 1985-1987.

Pharmacy and Therapeutics Committee, Westchester County Medical Center, Valhalla, N.Y., 1985-1987, Chairman, 1986-1987.

Research Protocol Review Committee, Westchester County Medical Center, Valhalla, N.Y., 1985-1987.

Committee for Protection of Human Subjects (IRB), New York Medical College, Valhalla, N.Y., 1985-1987.

 

TEACHING RESPONSIBILITIES AT UTMB:

 

Medical School:                 Course Co-Director, Gastrointestinal-Nutrition Course, Integrated Medical Curriculum (2nd Year), 2000-2003.

Yearly lectures as requested. 

Graduate School:                 Lectures in PM&CH Issues Course.  Lectures in Human Nutrition course.  Coordinator for Comprehensive Examination (1994). 

Coordinator for the Course "Methods in Clinical Investigation", renamed ”Clinical Research – Tools and Techniques”, 1995-current. 

Coordinator for the M.S.-Ph.D. Curriculum in Clinical Science, 1999-current. 

Graduate Student Course Advisory Committees:

Daher, Iyad – 2003-present

Granwehr, Bruno – 2003-present

Lillibridge, Kristy – 2004-present

Moukaddam, Nidal – 2003-present

Warneke, Richard – 2003-present

Masters Thesis Committees:

Membreno, Fernando 2002-2004

Zhao, Xiaotuan – 2003-2004

PhD Dissertation Committees

Huang, Yafei – 2003-present

Wang, Fen Wei – 2003-present

Cree, Melanie – 2004-present

Lillibridge, Kristy – 2004-present

Moukaddam, Nidal – 2004-present

Warneke, Richard – 2004-present

 

Attending Rounds:          Division of Gastroenterology and Department of Internal Medicine, several months yearly.

General Clinical Research Center:  Coordinator for educational activities and protocol development of the UTMB General Clinical Research Center, 1993-current. 

Clinical Research Education Office: Development of educational programs for clinical research at UTMB, 1999-current. 

 

MEMBERSHIP IN SCIENTIFIC AND PROFESSIONAL SOCIETIES:

 

American Federation for Medical Research (elected)

Southern Society for Clinical Investigation (elected)

American College of Physicians, Life Member, Fellow (elected)

American Association for the Study of Liver Diseases (elected)

New York Academy of Sciences (elected)

American Association for the Advancement of Science (elected)

American Gastroenterological Association (elected)

Sigma Xi, Life Member (elected)

Texas Medical Association

Galveston County Medical Society

Association for Patient Oriented Research (elected), Board of Directors 2004-current

 

BOARD CERTIFICATION:

American Board of Internal Medicine, Internal Medicine and Gastroenterology, 35646, 10/17/1972

 

LICENSURE INFORMATION:

 

Active:                   Texas (H3778, 6/18/88).

Inactive:                 Maryland (D00271, 6/9/65), New York State (103620, 6/20/69),

 

HONORS:

1964                        Goldberger Summer Fellowship in Nutrition, The American Medical Association

1977                        Research Career Development Award, 1 K04 GM00330 from the National Institutes of Health

2003 & 4                        America’s Top Doctors (Gastroenterology), Castle Connolly Medical Ltd. 

2004                        Nominated for Excellence in Teaching Award, Department of Internal Medicine, UTMB

ADDITIONAL INFORMATION:

Community, cultural and religious organizations:

Johns Hopkins University School of Medicine Alumni Association

Trinity Episcopal Church (Vestry Member 1991-1994, Senior Warden 1993, Senior Choir)

Saint Vincent's House Board of Trustees, 1997-1999 (3 years). 

Knights of Momus, Galveston, TX, 1995-present

BIBLIOGRAPHY:

PUBLISHED:

A.  Articles in peer-reviewed journals:

1.        Ginn HE, Anderson KE, Mercier RK, Stevens TW, Matter BJ. Camphor intoxication treated by lipid dialysis.  Journal of the American Medical Association 1968;203:164-165.

 

2.        Krohn K, Finlayson NDC, Jokelainen PT, Anderson KE, Prince AM. Electron microscopic and immunological observations on the serum- hepatitis (S.H.) antigen in primary biliary cirrhosis. Lancet 1970;2:230- 231.

 

3.        Finlayson NDC, Krohn K, Anderson KE, Jokelainen PT, Prince AM. Interrelations of hepatitis B antigen and auto-antibodies in chronic idiopathic liver disease.  Gastroenterology 1972;63:646-652.

 

4.        Finlayson NDC, Krohn K, Fauconnet MH, Anderson KE. Significance of serum complement levels in chronic liver disease. Gastroenterology 1972;63:653-659.

 

5.        Anderson KE, Kok E, Javitt NB. Bile acid synthesis in man: Metabolism of 7a-hydroxycholestero1-14C and 26-hydroxycholesterol-3H. Journal of Clinical Investigation 1972;51:112-117.

 

6.        Anderson KE, Finlayson NDC, Deschner EE. Intractable malabsorption with a flat jejunal mucosa and selective IgA deficiency, a case report with immunological and autoradiographic studies.  Gastroenterology 1974;67:709-716.

 

7.        Anderson KE, Sun S-C, Berg HS, Chang N-K. Liver function and histology in asymptomatic Chinese military personnel with hepatitis B antigenemia. American Journal of Digestive Diseases 1974;19:693-703.

 

8.        Sun S-C, Anderson KE, Hsu C-P, Kau S-L. Hepatocellular ultrastructure in asymptomatic hepatitis B antigenemia.  American Journal of Pathology 1974;97:373-379.

 

9.        Anderson KE, Stevens CE, Tsuei JJ, Lee W-C, Sun S-C, Beasley RP. Hepatitis B antigen in infants born to mothers with chronic hepatitis B antigenemia in Taiwan.  American Journal of Diseases of Children 1975;129:1389-1392.

 

10.     Sun S-C, Beasley RP, Anderson KE, Berg HS, Hsu C-P, Lee W-C. Serial liver biopsy observations in hepatitis B antigen carriers by light and electron microscopy. American Journal of Digestive Diseases 1976;21:366- 369.

 

11.     Van Peenan PFD, Anderson KE, See R, Nasution R. Serological evidence of arbovirus infection in febrile hospitalized patients in Jakarta,  Indonesia during 1970-71. Journal of Tropical Medicine and Hygiene 1974;77:244-249.

 

12.     Anderson KE, Joseph SW, Nasution R, Sunoto, Butler T, Van Peenan PFD, Irving GS, Sarosa TS, Watten RH. Febrile illnesses resulting in hospital admission:  A bacteriological and serological study in Jakarta, Indonesia. American Journal of Tropical Medicine and Hygiene 1976;25:116- 121.

 

13.     Anderson KE, Alvares AP, Sassa S, Kappas A. Studies in porphyria V. Drug oxidation rates in hereditary hepatic porphyria. Clinical Pharmacology and Therapeutics 1976;19:183-190.

 

14.     Alvares AP, Fischbein A, Sassa S, Anderson KE, Kappas A. Lead intoxication:  Effects on cytochrome P-450-mediated hepatic oxidations. Clinical Pharmacology and Therapeutics 1976;19:183-190.

 

15.     Chang RL, Wood AW, Dixon WR, Conney AH, Anderson KE, Eiseman J, Alvares AP. Antipyrine:  Radioimmunoassay in plasma and saliva following administration of a high and low dose to man. Clinical Pharmacology and Therapeutics 1976;20:219-226.

 

16.     Alvares AP, Anderson KE, Conney AH, Kappas, A. Interactions between nutritional factors and drug biotransformations in man. Proceedings of the National Academy of Sciences U.S.A. 1976;73:2501-2504.

 

17.     Anderson KE, Fischbein A, Kestenbaum D, Sassa S, Alvares AP, Kappas A. Plumbism from airborne lead in a firing range:  An unusual exposure to a toxic heavy metal. American Journal of Medicine 1977;63:306-312.

 

18.     Anderson KE, Sassa S, Peterson CM, Kappas A. Increased erythrocyte uroporphyrinogen-I-synthetase, d-aminolevulinic acid dehydratase and protoporphyrin in hemolytic anemias. American Journal of Medicine 1977;63:359-364.

 

19.     Pantuck EJ, Hsiao K-C, Conney AH, Garland WA, Kappas A, Anderson KE, Alvares AP. Effect of charcoal-broiled beef on phenacetin metabolism in man. Science 1976;194:1055-1057.

 

20.     Conney AH, Pantuck EJ, Hsiao K-C, Garland WA, Anderson KE, Alvares AP, Kappas A. Enhanced phenacetin metabolism in human subjects fed charcoal-broiled beef. Clinical Pharmacology and Therapeutics 1976;20:633-642.

 

21.     Kappas A, Anderson KE, Conney AH, Alvares AP. Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. Clinical Pharmacology and Therapeutics 1976;20:643-653.

 

22.     Anderson KE, Peterson CM, Alvares AP, Kappas A. Oxidative drug metabolism and inducibility by phenobarbital in sickle-cell anemia. Clinical Pharmacology and Therapeutics 1977;22:580-587.

 

23.     Alvares AP, Fischbein A, Anderson KE, Kappas A. Alterations in drug metabolism in workers exposed to polychlorinated biphenyls. Clinical Pharmacology and Therapeutics 1977;22:140-146.

 

24.     Fischbein A, Alvares AP, Anderson KE, Sassa S, Kappas A. Lead intoxication among demolition workers:  The effect of lead on the hepatic cytochrome P-450 system in man. Journal of Toxicology and Environmental Health 1977;3:431-437.

 

25.     Kappas A, Alvares AP, Anderson KE, Pantuck EJ, Pantuck CB, Chang R, Conney AH. Effect of charcoal-broiled beef on antipyrine and theophylline metabolism. Clinical Pharmacology and Therapeutics 1978;23:445-450.

 

26.     Anderson KE. Effects of antihypertensive drugs on hepatic heme biosynthesis, and evaluation of ferrochelatase inhibitors to simplify testing of drugs for heme pathway induction. Biochimica et Biophysica Acta 1978;543:313-327.

 

27.     Fischbein A, Daum S, Davidow B, Slavin G, Alvares AP, Sassa S, Anderson KE, Kappas A, Eisinger J, Blumberg WE, Winicow EH, Selikoff IJ. Lead hazard among ironworkers dismantling lead-painted elevated subway line in New York City. New York State Journal of Medicine 1978;78:1250- 1259.

 

28.     Pantuck EJ, Pantuck CB, Garland WA, Min B, Wattenberg LW, Anderson KE, Kappas A, Conney AH. Effect of dietary Brussels sprouts and cabbage on human drug metabolism.  Clinical Pharmacology and Therapeutics 1979;25:88-95.

 

29.     Anderson KE, Bradlow HL, Sassa S, Kappas A. Studies in porphyria VIII:  Relationship of the 5a-reductive metabolism of steroid hormones to clinical expression of the genetic defect in acute intermittent porphyria. American Journal of Medicine 1979;66:644-650.

 

30.     Alvares AP, Kappas A, Eiseman JL, Anderson KE, Pantuck CB, Pantuck EJ, Hsiao K-C, Garland WA, Conney AH. Intraindividual variations in drug disposition in man.  Clinical Pharmacology and Therapeutics 1979;26:407- 419.

 

31.     Anderson KE, Conney AH, Kappas A. Nutrition and oxidative drug metabolism in man: relative influence of dietary lipids, carbohydrate and protein. Clinical Pharmacology and Therapeutics 1979;26:493-501.

 

32.     Fishman J, Bradlow HL, Schneider J, Anderson KE, Kappas A. Radiometric analysis of biological oxidations in man: sex differences in estradiol metabolism. Proceedings of the National Academy of Sciences U.S.A. 1980;77:4957-4960.

 

33.     Fischbein A, Anderson KE, Sassa S, Lilis R, Kon S, Sarkozi L, Kappas A. Lead Poisoning from "do-it-yourself" heat guns for removing lead-based paint: report of two cases. Environmental Research 1981;224:425-431.

 

34.     Anderson PM, Reddy R, Anderson, KE, Desnick RJ. Characterization of the porphobilinogen deaminase deficiency in acute intermittent porphyria: immunological evidence for heterogeneity of the genetic defect. Journal of Clinical Investigation 1981;68:1-12.

 

35.     Anderson KE, Drummond GS, Freddara U, Sardana MK, Sassa S. Porphyrogenic effects and induction of heme oxygenase in vivo by d-aminolevulinic acid. Biochimica et Biophysica Acta 1981;676:289-299.

 

36.     Proia AD, McNamara DJ, Edwards KDG, Anderson KE. Effects of dietary pectin and cellulose on hepatic and intestinal mixed-function oxidations and hepatic HMG-CoA reductase in the rat. Biochemical Pharmacology 1981;30:2553-2558.

 

37.     Sassa S, Zalar GL, Poh-Fitzpatrick MB, Anderson KE, Kappas A. Studies in porphyria X: Functional evidence for a partial deficiency of ferrochelatase activity in mitogen-stimulated lymphocytes from patients with erythropoietic protoporphyria. Journal of Clinical Investigation 1982;69:809-815.

 

38.     Fischbein A, Wallace-Kahn J, Anderson KE, Sassa S, Kon S, Rohl AN, Kappas A. Lead poisoning in an art conservator restoring antique textiles. Journal of the American Medical Association 1982;247:2007-2009.

 

39.     Pantuck EJ, Pantuck CB, Anderson KE, Conney AH, Kappas A. Cigarette smoking and chlorpromazine dispositions and actions. Clinical Pharmacology and Therapeutics 1982;31:533-538.

 

40.     Schneider J, Kinne D, Fracchia A, Pierce V, Anderson KE, Bradlow HL, Fishman J. Abnormal oxidative metabolism of estradiol in women with breast cancer. Proceedings of the National Academy of Sciences U.S.A. 1982;79:3047-3051.

 

41.     Dean KS, Conneally PM, Sassa S, Anderson KE. Absence of close linkage between acute intermittent porphyria and the ABO, Rh, P, acid phosphatase, Pr, orosmucoid and pepsinogen loci.  Human Heredity 1982;32:189-192.

 

42.     Anderson KE, Freddara U, Kappas A. Induction of hepatic cytochrome P-450 by natural steroids:  Relationships to the induction of d-aminolevulinate synthase and porphyrin accumulation in the avian embryo. Archives of Biochemistry and Biophysics 1982;217:597-608.

 

43.     Schneider J, Bradlow HL, Strain G, Levin J, Anderson KE, Fishman J. Effects of obesity on estradiol metabolism:  Decreased formation of nonuterotropic metabolites. Journal of Clinical Endocrinology and Metabolism 1983;56:973-978

 

44.     Anderson KE, Schneider J, Pantuck EJ, Pantuck CB, Mudge GH, Welch LM, Conney AH, Kappas A. Acetaminophen metabolism in subjects fed charcoal-broiled beef. Clinical Pharmacology and Therapeutics 1983;34:369-374.

 

45.     Kappas A, Anderson KE, Conney AH, Pantuck EJ, Fishman J, Bradlow HL. Nutrition-endocrine interactions: Induction of reciprocal changes in the D4-5a-reduction of testosterone and the cytochrome P-450-dependent oxidation of estradiol by dietary macronutrients in man. Proceedings of the National Academy of Sciences, U.S.A. 1983;80:7646-7649.

 

46.     Anderson KE, Simionatto CS, Drummond GS, Kappas A. Tissue distribution and disposition of tin-protoporphyrin, a potent competitive inhibitor of heme oxygenase. J Pharmacology and Experimental Therapeutics 1984;228:327-333.

 

47.     Pantuck EJ, Pantuck CB, Anderson KE, Wattenberg LW, Conney AH, Kappas A. Effect of brussels sprouts and cabbage on drug conjugation in humans. Clinical Pharmacology and Therapeutics 1984;35:161-169.

 

48.     Proia AD, Edwards KDG, McNamara DJ, Anderson KE. Dietary influences on the hepatic mixed-function oxidase system in the rat after portacaval anastomosis. Gastroenterology 1984;86:618-626.

 

49.     Rosenberg DW, Anderson KE, Kappas A. The potent induction of intestinal heme oxygenase by the organotin compound, bis(tri-n- butyltin)oxide. Biochemical and Biophysical Research Communications 1984;119:1022-1027.

 

50.     Kappas A, Drummond GS, Simionatto CS, Anderson KE. Control of heme oxygenase and plasma levels of bilirubin by a synthetic heme analogue, tin-protoporphyrin. Hepatology 1984;4:336-341.

 

51.     Anderson KE, Kappas A, Conney AH, Bradlow HL, Fishman J. The influence of dietary protein and carbohydrate on the principal oxidative biotransformations of estradiol in normal subjects.  Journal of Clinical Endocrinology and Metabolism 1984;59:103-107.

 

52.     Anderson KE, Spitz IM, Sassa S, Bardin CW, Kappas A. Prevention of cyclical attacks of acute intermittent porphyria with a long-acting agonist of luteinizing hormone-releasing hormone.  New England Journal of Medicine 1984;311:643-645.

 

53.     Simionatto CS, Anderson KE, Sassa S, Drummond GS, Kappas A. Fluorometric measurement of tin-protoporphyrin in biological samples. Analytical Biochemistry 1984;14:213-219.

 

54.     Simionatto CS, Anderson KE, Drummond GS, Kappas A. Studies on the mechanism of Sn-protoporphyrin suppression of hyperbilirubinemia:  inhibition of heme oxidation and bilirubin production. Journal of Clinical Investigation 1985;75:513-521.

 

55.     Kappas A, Simionatto CS, Drummond GS, Sassa S, Anderson KE. The liver excretes large amounts of heme into bile when heme oxygenase is inhibited competitively by Sn-protoporphyrin. Proceedings of the National Academy of Sciences U.S.A. 1985;82:896-900.

 

56.     Anderson KE, Simionatto CS, Drummond GS, Kappas A. Disposition of tin-protoporphyrin and suppression of hyperbilirubinemia in humans. Clinical Pharmacology and Therapeutics 1986;39:510-520.

57.     Anderson KE, Rosner W, New MI, Pang S, Wissel PS, Kappas A. The ratio of dietary protein to carbohydrate alters reciprocally the plasma levels of testosterone and cortisol and their respective binding globulins in man. Life Sciences 1987;40:1761-1768.

 

58.     Wissel PS, Sordillo P, Anderson KE, Sassa S, Savillo RL, Kappas A. Porphyria cutanea tarda associated with the acquired immune deficiency syndrome. American Journal of Hematology 1987;25:107-113.

 

59.     Anderson KE, Goeger DE, Carson RW, Lee S-MK, Stead RB. Erythropoietin for treatment of porphyria cutanea tarda in a patient on long-term hemodialysis.  New England Journal of Medicine 1990; 322:315-317.

 

60.     Anderson KE, Spitz IM, Bardin CW, Kappas A. A GnRH analogue prevents cyclical attacks of porphyria. Archives of Internal Medicine 1990;150:1469-1474.

 

61.     Winkler M, Anderson KE. Vampires, porphyria and the media. Perspectives in Biology and Medicine 1990; 33:598-611.

 

62.     Anderson KE, McCleery RB, Vesell ES, Vickers FF, Kappas A.  Diet and cimetidine induce comparable changes in theophylline metabolism in normal subjects. Hepatology 1991; 13:941-946.

 

63.     Goeger DE, Anderson KE. Coumarin-induced changes in d-aminolevulinic acid synthase and cytochrome P-450 mixed function oxidase activities in the chick embryo liver .  Food and Chemical Toxicology 1991; 29: 145-151.  

 

64.     Pantuck EJ, Pantuck CB, Kappas A, Conney AH, Anderson KE. Effects of protein and carbohydrate content of the diet on drug conjugation. Clinical Pharmacology and Therapeutics1991; 50: 254-258. 

 

65.     Goeger DE, Anderson KE. Biochemical characterization of coumarin hydroxylase activity in chick embryo liver microsomes.  Biochemical Pharmacology 1992; 43:363-369.     

 

66.     Carson RW, Dunnigan EJ, DuBose TDJr, Goeger DE, Anderson KE. Removal of plasma porphyrins with high-flux hemodialysis in porphyria cutanea tarda associated with end-stage renal disease. Journal of the American Society of Nephrology 1992;2:1445-1450.

 

67.     McConnell R, Anderson K, Russell W, Anderson KE, Clapp R, Silbergeld EK, Landrigan PJ. Angiosarcoma, porphyria cutanea tarda and probable chloracne in a worker exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin-contaminated waste oil. British Journal of Industrial Medicine 1993:50:699-703. 

 

68.     Barohn RJ, Sanchez JE, Anderson KE. Acute peripheral neuropathy due to hereditary coproporphyria. Muscle and Nerve 1994; 17:793-799. 

 

69.     Chen C-H, Astrin KH, Lee G, Anderson KE, Desnick RJ. Acute intermittent porphyria: identification and expression of exonic mutations in the hydroxymethylbilane synthase gene: an initiation codon missense mutation in the housekeeping transcript causes "variant acute intermittent porphyria" with normal expression of the erythroid-specific enzyme.  Journal of Clinical Investigation 1994; 94:1927-1937. 

 

70.     Lu L-JW, Anderson KE, Gomez G, Nealon WH. Decreased plasma levels of cholecystokinin in healthy males after chronic ingestion of a heat-treated soya product. Cancer Letters 1995;90:149-155.

71.     Ramamujam VMS, Egger NG, Alcock NW, Anderson KE. Measurement of lanthanum and lutetium in metal-containing texaphrins by inductively coupled plasma-mass spectroscopy. Atomic Spectroscopy, 1995;16:211-216. 

72.     Lu L-JW, Grady JJ, Marshall MV, Ramanujam VMS, Anderson KE. Altered time course of urinary daidzein and genistein excretion during chronic soya diet in healthy subjects. Nutrition and Cancer 1995;24:311-323.

73.     Egger NG, Motamedi M, Pow-Sang M, Orihuela E, Anderson KE. Accumulation of porphyrins in plasma and tissues of dogs after d-aminolevulinic acid administration: implications for photodynamic therapy. Pharmacology 1996;52:362-370.

74.     Lu L-JW, Lin S-N, Grady JJ, Nagamani M, Anderson KE. Altered kinetics and extent urinary daidzein and genistein excretion during chronic soya exposure. Nutrition and Cancer 1996;26:289-302.

75.     Egger NG, Goeger DE, Anderson KE. Effects of chloroquine in hematoporphyrin-treated animals. Chemico-Biological Interactions 1996;102:69-78. 

76.     Egger NG, Schoenecker JA Jr, Gourley WK, Motamedi M, Anderson KE, Weinman SA. Photosensitization of experimental hepatocellular carcinoma after d-aminolevulinic acid. Journal of Hepatology 1997;26:913-920. 

77.     Daniell WE, Stockbridge HL, Labbe RF, Woods JS, Anderson KE, Bissell DM, Bloomer JR, Ellefson RD, Moore MR, Pierach CA, Schreiber WE, Tefferi A, Franklin GM. Environmental chemical exposures and disturbances of heme synthesis. Environmental Health Perspectives 1997;105, Suppl 1:37-53. 

78.     Sinclair PR, Gorman N, Shedlofsky SI, Honsinger C, Sinclair JF, Karagas MR, Anderson KE. Ascorbic acid deficiency in porphyria cutanea tarda. Journal of Laboratory and Clinical Medicine 1997;130:197-201.

79.     Goeger DE, Anderson KE, Hsie AW. Coumarin chemoprevention against aflatoxin B1 induced gene mutation in a mammalian cell system: a species difference in mutagen activation and protection with chick embryo and rat liver S9. Environmental and Molecular Mutagenesis 1998;32:64-74.

80.       Lu L-JW, Anderson KE. Sex and long-term soy diets affect the metabolism and excretion of soy isoflavones in humans. American Journal of Clinical Nutrition 1998;68 (suppl):1500S-1504S.

81.     Goeger DE, Hsie AW, Anderson KE. Co-mutagenicity of coumarin (1,2-benzopyrone) with aflatoxin B1 and human liver S9 in mammalian cells. Food and Chemical Toxicology, 37:581-589, 1999. 

82.       Lu L-J, Cree M, Josyula S, Nagamani M, Grady JJ, Anderson KE. Increased urinary excretion of 2-hydroxyestrone but not 16a-hydroxyestrone in premenopausal women during a soya diet containing isoflavones. Cancer Research 2000; 60:1299-1305. 

83.       Wan XS, Lu LJ, Anderson KE, Ware JH, Kennedy AR. Urinary excretion of Bowman-Birk inhibitor in humans after soy consumption as determined by monoclonal antibody-based immunoassay. Cancer Epidemiology Biomarkers & Prevention 2000; 9:741-747. 

84.       Ramdall RB, Cunha L, Astrin KH, Katz DR, Anderson KE, Glucksman M, Bottomley SS, Desnick RJ: Acute intermittent porphyria: novel missense mutations in the human hydroxymethylbilane synthase gene. Genetics in Medicine 2000;2:290-5.

85.       Barone GW, Gurley BJ, Anderson KE, Ketel BL, Abul-Ezz SR. The tolerability of newer immunosuppressive medications in a patient with acute intermittent porphyria. J Clin Pharmacol. 2000;41:113-115. 

86.       Turton-Weeks S, Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR, Anderson KE: Pretransplant evaluation of a patient with acute intermittent porphyria. Progress in Transplantation 2001;41:214-216.

87.       Frank J, Jugert FK, Merk HF, Kalka K, Goerz G, Anderson K, Bickers DR, Poh-Fitzpatrick MB, Christiano AM: A spectrum of novel mutations in the protoporphyrinogen oxidase gene in 13 families with variegate porphyria. J Invest Dermatol 2001;116:821-3.

88.       Egger NE, Goeger DE, Payne DA, Miskovsky EP, Weinman SA, Anderson KE. Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C and inherited uroporphyrinogen decarboxylase deficiency. Digestive Diseases and Sciences 2002; 47:419-426.

89.     Poh-Fitzpatrick MB, Wang X, Anderson KE, Bloomer JE, Bolwell B, Lichtin AE: Erythropoietic protoporphyria: altered phenotype after bone marrow transplantation for myelogenous leukemia in a patient heteroallelic for ferrochelatase gene mutations. Journal of the American Academy of Dermatology 2002;46:861-866. 

90.     Lee C, Qiao X, Goeger DE, Anderson KE: Fluorometric measurement of 5-aminolevulinic acid in serum. Clinica Chimica Acta, 2004;347:183-188. 

91.     Anderson KE, Bloomer JR, Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR, Desnick RJ: Recommendations for the diagnosis and treatment of the acute porphyrias. Annals of Internal Medicine 2005;142:439-50. 

92.     Huang Y, Cao S, Nagamani M, Anderson KE, Grady J, Lu L-JW: Decreased circulating levels of tumor necrosis factor-alpha (TNF-a) in postmenopausal women during consumption of soy containing isoflavones. Journal of Clinical Endocrinology and Metabolism 2005;90:3956-62. 

93.     Nhan S, Anderson KE, Nagamani M, Grady JJ, Lu LJ: Effect of a soymilk supplement containing isoflavones on urinary f2 isoprostane levels in premenopausal women. Nutrition and Cancer 2005;53(1):73-81.

94.     Akagi R, Kato N, Inoue R, Anderson KE, Jaffe EK, Sassa S: delta-Aminolevulinate dehydratase (ALAD) porphyria: The first case in North America with two novel ALAD mutations. Molecular Genetics and Metabolism. Published on line, Dec 9, 2005.

95.     Akagi R, Inoue R, Muranaka S, Tahara T, Taketani S, Anderson KE, Phillips JD, Sassa S. Dual gene defects involving d-aminolaevulinate dehydratase and coproporphyrinogen oxidase in a porphyria patient.  British Journal of Haematology. 2006;132:237-243. 

B.  Other:

1.        Anderson KE, Javitt NB. Bile formation.  In: Becker FF, ed. The Liver: Normal and Abnormal Functions, Part A. New York: Marcel Dekker, Inc. 1974;372-400.

 

2.        Bradlow HL, Anderson KE, Kappas A. Differences between cutaneous and hepatic steroid D4-5a-reductase in patients with acute intermittent porphyria.  In: Doss M, ed. Porphyrins in Human Diseases. S. Karger, Basel, 1976:173-178.

 

3.        Anderson KE, Bodansky O, Kappas A. Effects of oral contraceptives on vitamin metabolism. Advances in Clinical Chemistry 1976;18:247-287.

 

4.        Kappas A, Alvares AP, Anderson KE, Garland WA, Pantuck EJ, Conney AH. The regulation of human drug metabolism by nutritional factors.  In: Ullrich V, Roots I, Hildebrandt A, Estabrook RW, Conney AH, eds. Microsomes and Drug Oxidations. Proceedings of the Third International Symposium. New York: Pergamon Press 1977:703-708.

 

5.        Conney AH, Pantuck EJ, Kuntzman R, Kappas A, Anderson KE, Alvares AP. Nutrition and chemical biotransformations in man. Proceedings of the 4th Deer Lodge Conference on Clinical Pharmacology. Clinical Pharmacology and Therapeutics 1977;22:707-720.

 

6.        Alvares AP, Kappas A, Anderson KE, Pantuck EJ, Conney AH. Nutritional factors regulating drug biotransformations in man. In: Olive G, ed. Advances in Pharmacology and Therapeutics, Vol. 8. Oxford: Pergamon Press 1978:43-51.

 

7.        Conney AH, Pantuck EJ, Pantuck CB, Buening M, Jerina DM, Fortner DG, Alvares AP, Anderson KE, Kappas A. Role of environment and diet in the regulation of human drug metabolism, In: Estabrook RW, Lindenlaub E, eds. The Induction of Drug Metabolism. F. K. Schattauer Verlag: Stuttgart 1978:583-605.

 

8.        Anderson HA, Wolff MS, Lilis R, Holstein EC, Valciukas JA, Anderson KE, Petrocci M, Sarkozi L, Selikoff IJ. Symptoms and clinical abnormalities following ingestion of polybrominated biphenyl contaminated food products. Annals of the New York Academy of Sciences 1979;320:684- 702.

 

9.        Alvares AP, Pantuck EJ, Anderson KE, Kappas A, Conney AH. Regulation of drug metabolism in man by environmental factors. Drug Metabolism Reviews 1979;9:185-205.

 

10.     Conney AH, Buening MK, Pantuck EJ, Pantuck CB, Fortner JG, Anderson KE, Kappas A. Regulation of human drug metabolism by dietary factors.  In: Evered D, Lawrenson G, eds. Environmental Chemicals, Enzyme Function and Human Disease. Proceedings of the Ciba Foundation Symposium. Amsterdam: Excerpta Medica 1980:147-167.

 

11.     Fishman J, Bradlow HL, Schneider J, Anderson KE, Kappas A. Study of differences of estradiol metabolism between men and women by means of in vivo radiometric analysis.  Transactions of the Association of American Physicians 1980;93:295-304.

 

12.     Conney AH, Pantuck EJ, Pantuck CB, Fortner JG, Alvares AP, Anderson KE, Kappas A. Variability in human drug metabolism.  In: Turner P, ed. Clinical Pharmacology and Therapeutics. Proceedings of Plenary Lectures, Symposia and Therapeutic Sessions, The First World Conference on Clinical Pharmacology and Therapeutics, London, 1980. London: MacMillan Publishers, Ltd.  pp 51-62.

 

13.     Anderson KE, Sassa S, Kappas A. Acute intermittent porphyria (letter to editor). Ann Int Med 1981;95:784-785.

 

14.     Anderson KE, Kappas A. Hormones and liver function, chapter 6.  In: Schiff L, Schiff ER, eds.  Diseases of the Liver, 5th edition.  Philadelphia: J. B. Lippincott Company. 1982:167-235. 

 

15.     Kappas A, Sassa S, Anderson KE. The porphyrias.  In: Stanbury JB, Wyngaarden JB, Fredrickson DS, Goldstein JL, Brown MS, eds. The Metabolic Basis of Inherited Disease, 5th edition. New York: McGraw-Hill Book Company 1982:1301-1384.

 

16.     Anderson KE, Conney AH, Kappas A. Nutritional influences on chemical biotransformations in humans. Nutrition Reviews 1982;40:161-171.

 

17.     Anderson KE, Sassa S, Kappas A. The porphyrias. In: Kaye D, Rose LF, eds. Fundamentals of Internal Medicine. St. Louis: C. V. Mosby 1983;596- 605.

 

18.     Anderson KE, Sassa S, Kappas A. The porphyrias. In: Rose LF, Kaye D, eds. Internal Medicine for Dentistry. St. Louis: C. V. Mosby 1983:1246- 1255.

 

19.     Anderson KE, Kappas A. The porphyrias. In: Conn HF, ed. Current Therapy. Philadelphia: W.B. Saunders Co. 1983:328-336.

 

20.     Sassa S, deVerneuil H, Anderson KE, Kappas A. Purification and properties of human uroporphyrinogen decarboxylase:  Immunological demonstration of the enzyme defect in porphyria cutanea tarda.  Transactions of the Association of American Physicians 1983;96:65-75.

 

21.     Anderson KE.  Porphyria cutanea tarda (statement prepared for the Subcommittee on Compensation, Pension and Insurance, Committee on Veterans Affairs, U.S. House of Representatives, and presented at a hearing before the subcommittee in Washington, D.C. on July 12, 1983).  In: H.R. 1961 - Vietnam Veterans Agent Orange Relief Act, Serial No. 98-23, U.S. Government Printing Office, Washington 1983.

 

22.     Anderson KE, Kappas A. Dietary influences on the metabolism of theophylline and other drugs in humans.  In: Jonkman JHG, Jenne JW, Simons FER, eds. Sustained Release Theophylline in the Treatment of Chronic Reversible Airways Obstruction, International Workshop. Amsterdam: Excerpta Medica 1984:83-90.

 

23.     Anderson KE, Kappas A. The porphyrias.  In: Rakel RE, ed. Conn's Current Therapy. Philadelphia: W.B. Saunders Co. 1984:320-327.

 

24.     Anderson KE, Kappas A. Diet regulates drug and hormone metabolism in humans:  Experimental findings and clinical implications.  In: Caldwell J, Paulson GD, eds.  Foreign Compound Metabolism. London and Philadelphia: Taylor & Francis 1984:299-308.

 

25.     Anderson KE, Pantuck EJ, Conney AH, Kappas A. Nutrient regulation of chemical metabolism in humans. Federation Proceedings 1985;44:130-133.

 

26.     Anderson KE, Spitz IM, Sassa S, Bardin CW, Kappas A. Intranasal luteinizing hormone-releasing agonist for prevention of cyclical attacks of acute intermittent porphyria.  In: Nordman Y, ed.  Porphyrins and Porphyrias. London: John Libbey and Co. 1986:225-231.

 

27.     Sassa S, Anderson KE, Kappas A. Uroporphyrinogen decarboxylase: Genetic defects and inhibition by environmental chemicals.  In: Nordman Y, ed. Porphyrins and Porphyrias. London: John Libbey and Co. 1986:45- 53.

 

28.     Anderson KE, Conney AH, Kappas A. Nutrition as an environmental influence on chemical metabolism in man.  In: Kalow W, Goedde W, Agarwal DP, eds. Ethnic Differences in Reactions to Drugs and Xenobiotics.  New York: Alan R. Liss, Inc. 1986:39-54.

 

29.     Anderson KE. Drug-nutrient interrelationships and the elderly.  In: Dunkle RE, Petot G, Ford AB, eds. Food, Drugs, and Aging. New York: Springer 1986:127-137.

 

30.     Anderson KE.  Influences of diet and nutrition on clinical pharmacokinetics.  Clinical Pharmacokinetics 1988;14:325-346.

 

31.     Anderson KE. LHRH analogues for hormonal manipulation in acute intermittent porphyria.  Seminars in Hematology 1989;26:10-15. 

 

32.     Anderson KE.  The porphyrias.  In:  Williams WJ, Beutler E, Erslev AJ, Lichtman MA, eds.  Hematology, 4th edition.  New York: McGraw-Hill1990: 722-742. 

 

33.     Anderson KE. Nutritional effects on hepatic drug metabolism in the elderly. In: Prinsley DM, Sandstead HH eds. Nutrition and Aging. New York: Alan R. Liss, 1990: 263-277.

 

34.     Proia AD, Anderson KE. The porphyrias. In: Gold D. H., Weingeist TA, eds. The Eye in Systemic Disease. Philadelphia: J. B. Lippincott 1990:398-401.

 

35.     Anderson KE, Sassa S, Kappas A. The porphyrias. In: Rose LF, Kaye D, eds. Internal Medicine for Dentistry, 2nd edition. St. Louis: C. V. Mosby 1990:1102-1108.

 

36.     Desnick RJ, Roberts AJ, Anderson KE.  The inherited porphyrias.  Chapter 98.  In: Emery AEH, Rimoin DL, eds. Principles and Practice of Medical Genetics, 2nd edition. Edinburgh: Churchill Livingston 1990: 1747-1770.  

 

37.     Anderson KE. The porphyrias.  In: Rakel RE, ed. Conn's Current Therapy. Philadelphia: W.B. Saunders Co. 1991:391-397.

 

38.     Desnick RJ, Anderson KE. The porphyrias.  In: Hoffman R., Benz EJJr, Shattil, SJ, Furie B, Cohen H, eds.  Hematology: Basic Principles and Practice.  New York: Churchill Livingston 1991:350-367. 

 

39.     Anderson KE.  The Nation's Health, third edition (book review).  Medical Humanities Review, 1991; 5:99-100. 

 

40.     Anderson KE, Kappas A.  Dietary regulation of cytochrome P450. Annual Review of  Nutrition 1991;11:141-167.

 

41.     Anderson KE. The porphyrias. In: Wyngaarden JB, Smith LH Jr., Bennett CJ, Plum F, ed. Cecil Textbook of Medicine,19th edition. Philadelphia: Saunders 1992: 1126-1132.

 

42.     Anderson KE. Pseudoporphyria and porphyria cutanea tarda (letter to editor). Journal of Pediatrics, 1993;123:841-842. 

 

43.     Desnick RJ, Anderson KE. The porphyrias. In: Hoffman R, Benz EJJr, Shattil SJ, Furie B, Cohen H, Silberstein LE, eds. Hematology: Basic Principles and Practice, 2nd edition. New York: Churchill Livingston 1994:523-545.

44.     Egger N, Anderson KE. Nutrition/metabolism classic: neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. Nutrition 1995;11:180-181. 

45.     Anderson KE, Goeger DE, Bessman DJ. Asymptomatic erythrocyte disorder presenting as increased porphobilinogen deaminase and uroporphyrinogen decarboxylase (letter to editor). Clinical Chemistry 1995;41:1670.

46.     Anderson KE. The porphyrias (Chapter 187). In: Bennett CJ, Plum F, eds. Cecil Textbook of Medicine, 20th edition. Philadelphia: Saunders 1996: 1124-1131. 

47.     Anderson KE. The porphyrias (Chapter 14). In: Zakim D, Boyer T, eds. Hepatology, 3rd edition. Philadelphia: W.B. Saunders Co. 1996:417-463. 

48.     Anderson KE. The porphyrias (Chapter 27). In: Blau N, Duran, M, Blaskovics ME, eds. Physician's Guide to the Laboratory Diagnosis of Metabolic Diseases, London: Chapman and Hall Medical 1996:437-451. 

49.     McGovern MM, Anderson KE, Astrin KH, Desnick RJ.  Inherited porphyrias.  Chapter 93.  In: Rimoin DL, Conner JM, Pyeritz RE, eds. Emery and Rimoin's Principles and Practice of Medical Genetics, 3rd edition. Edinburgh: Churchill Livingston 1996:2009-2036. 

50.     Anderson KE, Kappas A. Acute porphyria. In: Griffin JW, Johnson RT, eds. Current Therapy in Neurologic Disease 5th edition. St. Louis: Mosby 1997:324-328. 

51.     Anderson KE, Kappas A. The porphyrias. In: Rakel RE, ed. Conn's Current Therapy. Philadelphia: W.B. Saunders Co. 1997:433-438. 

52.       Anderson KE. Porphyrias. In: Berkow R, Beers MH, Fletcher AJ, ed. The Merck Manual of Medical Information, Home Edition. Whitehouse Station, NJ: Merck Research Laboratories 1997:687-690.

53.       Miskovsky EP, Reeves-Darby VG, Anderson KE. Gastroenterology (Chapter 35). In: Viegas SF, Dunn K, ed. Telemedicine: Practicing in the Information Age. Philadelphia: Lippincott-Raven Publishers 1998:257-259.

54.       Anderson KE. The porphyrias (Chapter 17). In: Beers MH, Berkow R, ed. The Merck Manual of Diagnosis and Therapy. Whitehouse Station, NJ: Merck Research Laboratories 1999:185-200.

55.       Furuyama K, Kondo M, Fujita H, Hayashi N, Anderson KE, Sassa S: Absence of C282Y and H63D mutations of the hemochromatosis gene in Japanese patients with sideroblastic anemia (letter to editor). American Journal of Hematology 1999; 61:276.

56.     Anderson KE. The porphyrias (Chapter 219). In: Goldman, L., Bennett CJ, eds. Cecil Textbook of Medicine, 21st edition. Philadelphia: W.B. Saunders Co., 2000; 1123-1132. 

57.     Egger NG, Goeger DE, Anderson KE. The porphyrias. In: Fernandes J, Saudubray J-M, Van den Berghe G, eds. Inborn Metabolic Diseases: Diagnosis and Treatment. Berlin:Springer; 2000: 371-382. 

58.     Anderson KE, Sassa S, Bishop D, Desnick RJ. Disorders of heme biosynthesis: X-Linked sideroblastic anemia and the porphyrias.  In: Scriver CR, Beaudet AL, Sly WS, Valle D, Vogelstein B, Childs B, eds. The Metabolic and Molecular Basis of Inherited Disease, 8th edition. New York: McGraw-Hill Book Company, 2000: 2991-3062.

59.     Desnick RJ, Anderson KE, Astrin KH.  Inherited porphyrias.  In: Rimoin DL, Conner JM, Pyeritz RE, Korf, BR, eds. Emery and Rimoin's Principles and Practice of Medical Genetics, 4th edition. Edinburgh: Churchill Livingston, 2002:2586-2623. 

60.     Anderson KE, Greenblatt D.  Assessing and managing drug-nutrient interactions.  Journal of the American Pharmaceutical Association 2002: 42, Suppl 1:2-3.  (A summary of separate oral presentations by the authors in a symposium at the annual meeting of the association.) 

61.     Anderson KE. The porphyrias (Chapter 11). In: Zakim D, Boyer T, eds. Hepatology, 4th edition. Philadelphia: W.B. Saunders Co., 2003:291-346. 

62.     Anderson KE. Approaches to treatment and prevention of human porphyrias (Chapter 94), In: Kadish KM, Smith K, Guilard R eds. Porphyrin Handbook, Part II. San Diego, Academic Press, 2003, vol 14, pp 247-284. 

63.       Anderson KE. The porphyrias (Chapter 223). In: L. Goldman and D. Ausiello., eds.  Cecil Textbook of Medicine. Philadelphia, W.B. Saunders Co., 2004: 1292-1300. 

64.       Anderson KE. Effects of specific foods and non-nutritive dietary components on drug metabolism, in Boullata JI, Armenti VT, Malone M (eds): Handbook of Drug-Nutrient Interactions. Totowa, NJ, Humana Press, 2004, pp 155-173.

65.       Murray BE, Anderson KE, Arnold K, Bartlett JG, Carpenter, CC, Falkow S, Hartman JT, Lehman T, Reid TW, Ryburn FM Jr., Sack RB, Struelens MJ, Young LS, Greenough WB III, Destroying the Life and Career of a Valued Physician-Scientist Who Tried to Protect Us from Plague: Was It Really Necessary? Clinical Infectious Diseases 2005; 40:1644-1648.   

66.     Anderson KE. The porphyrias (Chapter 73). In: Zakim and Boyer’s Hepatology, 5th edition. Philadelphia: Elsevior, in press. 

SUBMITTED

1.        Anderson KE, Pantuck EJ, Pantuck CB, A.H. C, Kappas A. The influence of a controlled diet on intraindividual variability in drug metabolism. Submitted 

2.        Goeger DE, Vadhanavikit S, Anderson KE. Effects of estrogen and antioxidants in hexachlorobenzene porphyria in rats. Submitted. 

3.        Akagi R, Kato N, Hanafusa R, Anderson KE, Sassa S.  Novel mutations of d-aminolevulinate dehydratase (ALAD) in the first case of ALAD deficiency porphyria (ADP) in North America. Submitted.